


Good MornING Asia - 21 January 2020

So far, the Wuhan flu story is being treated as if it were an interesting aside - we suspect this may become a top headline in the coming days and weeks

In this bundle



Flu season goes viral

So far, the Wuhan flu story is being treated as if it were an interesting aside - I suspect this may become a top headline in the coming days and weeks

By Robert Carnell



Asia Morning Bites

ASEAN Morning Bytes


Central banks back in the limelight in Asia with the Bank of Japan meeting today, Bank Indonesia tomorrow, and Bank Negara Malaysia on Thursday

By Nicholas Mapa

Opinion | 20 January 2020

Flu season goes viral

So far, the Wuhan flu story is being treated as if it were an interesting aside - I suspect this may become a top headline in the coming days and weeks



Corona virus

IMF upgrades global GDP

One of the top stories on the newswires today is that the IMF has trimmed its growth forecast to 3.3%, but still sees it picking up in 2020 from 2.9% in 2019. A few things are wrong with this story.

1. It fails to mention that the 2019 figures is, according to some approaches, consistent with the IMF definition of global recession. That helps put 3.3% into perspective. It isn't great. But it isn't recession at least.
2. IMF forecasts (like most other forecasts) are not worth the paper they are written on. So 2020 is not as bad as 2019? Following the trade truce, and the bottoming of the tech slump, and all the monetary easing from the Fed and others in 2019? I think a child of six could probably have figured that one out. And as for whether the number is 3.3% or 3.4% or 3-point anything else, if you can't forecast with any degree of accuracy, then it is probably better not to give the sense that you can by using decimal places. Why not just say, it's better than 2019, but still terribly weak. That just about conveys all you need to know without providing any spurious scientific accuracy (I wish I could get away with that too, but it seems we seek comfort in such meaningless numbers).

You see the real problem with all of this is not the forecasts themselves, but it is that a story that

doesn't make it into the top section this morning, might well do in a few weeks, and that is Wuhan flu, as it has come to be known.

Pass the paracetamol

Those of you old enough to remember the SARS epidemic will remember all too well how a disease which only infected [8098 people worldwide, and resulted in only 774 deaths in 37 countries \(thanks Wikipedia\)](#), a mortality rate of less than 10%, led to such widespread public alarm that it plunged Hong Kong into recession, and caused a serious slowdown in China. Other countries badly affected, included Canada, which held the symposium on the disease, bringing in health workers from around the world who had been exposed to the disease and stuffed them together into a conference hall in Toronto. Please, if there is a symposium on this new outbreak, do it by skype.

To put all this into perspective, in the 2017/2018 season, in the US, flu, the normal common all-garden variety, not SARS, not MERS, not any fancy animal crossover hybrid coronavirus, [killed 80,000 people according to the centre for disease control \(CDC\)](#). Although this was a high tally for a normal year, it didn't receive much attention, because each year, flu kills tens of thousands of people anyway.

What scared people about SARS is the mortality rate. In the UK in 2019, three times more people died of flu than normal, but still, the total was only 135 deaths from a total estimated infection of over 35 thousand (total population 65 million). That is a mortality rate of less than 0.4%, and normally it would be far lower.

Put into context, your chances of contracting and dying of SARS, were statistically far less than of dying of regular flu. But the response of the population of countries where there was a perceived greater risk, was huge. Presumably, the reasoning was, if I do get it, the odds aren't great.

People didn't take public transport, stayed away from work, stayed away from shops, restaurants, cinemas, conferences etc. The impact from the disease was massive on the economy, but almost all of it indirect, due to the precautionary behaviour of the population.

Cases of Wuhan flu have now risen to more than 300, though researchers at Imperial College, London suspect that the numbers may already be north of 1700.

I'm no doctor, but I do think I understand human nature well enough to realise the potential for another economic hit to growth from this source. That's certainly not in the IMF's global growth model.

Thailand relaxes mortgage lending rules

(Prakash Sakpal writes): The Bank of Thailand announced the relaxation of mortgage lending rules yesterday. The loan-to-value (LTV) limit for the first home of more than THB 10 million was raised to 90% from 80%, while buyers at all prices were also allowed an additional 10% loan for furniture and decorations. There is also easing of LTV rules for second home buyers and the risk-weight requirement for some home mortgages. The latest easing of mortgage rules follows tightening in April 2019 and we don't see these carrying any material impact for the economy plagued by persistently weak domestic demand.

IMF downgrades Indian growth prospects

(Prakash also adds): In a sharp downgrade, the IMF (reinforcing the earlier point about the value of forecasts) lowered India's FY2019-20 growth forecast to 4.8% from 6.1% in October. It cited slowing domestic demand and shadow bank stress amidst a weak global economic environment. No surprises here. The limited policy space after a significant easing of both fiscal and monetary policies last year is likely to keep the growth outlook weak for the coming year.

Author

Robert Carnell

Regional Head of Research, Asia-Pacific

robert.carnell@asia.ing.com

ASEAN Morning Bytes

Central banks back in the limelight in Asia with the Bank of Japan meeting today, Bank Indonesia tomorrow, and Bank Negara Malaysia on Thursday



EM Space: IMF growth projections show gradual recovery

- **General Asia:** The IMF nudged down its 2020 growth forecast for the ASEAN to 4.8% from 4.9% and for 2021 to 5.1% from 5.2%, while global growth is expected to settle at 3.3% this year (down from 3.4%). Asian central banks back in focus with the Bank of Japan meeting today, Bank Indonesia tomorrow, and Bank Negara Malaysia on Thursday.
- **Thailand:** The Bank of Thailand announced the relaxation of mortgage lending rules yesterday. The loan-to-value (LTV) limit for the first home of more than THB 10 million was raised to 90% from 80%, while buyers at all prices were also allowed an additional 10% loan for furniture and decorations. There is also easing of LTV rules for second home buyers and the risk-weight requirement for some home mortgages. The latest easing of mortgage rules follows tightening in April 2019 and we don't see these carrying any material impact for the economy plagued by persistently weak domestic demand.
- **Philippines:** The overall balance of payments (BoP) showing a surplus of \$7.8bn in 2019 as the financial account swung into surplus in the last year on improved investor sentiment, while the current account remained in deficit albeit some narrowing of trade deficit. We see the BoP reverting back to the deficit this year as a surge in import demand from the infrastructure spending plan is likely to swell the current account deficit.

What to look out for: Asian central bank meetings and Trump impeachment

- Taiwan GDP (21 January)
- Hong Kong inflation (21 January)
- Bank of Japan meeting (21 January)
- Philippines agriculture output (22 January)
- Thailand trade (22 January)
- Malaysia inflation (22 January)
- Taiwan industrial production (22 January)
- US existing home sales (22 January)
- Philippines GDP (23 January)
- Singapore inflation (23 January)
- Bank Indonesia meeting (23 January)
- ECB meeting (23 January)
- US PMI manufacturing (24 January)

Author

Nicholas Mapa

Senior Economist, Philippines

nicholas.antonio.mapa@asia.ing.com

Disclaimer

This publication has been prepared by the Economic and Financial Analysis Division of ING Bank N.V. ("ING") solely for information purposes without regard to any particular user's investment objectives, financial situation, or means. *ING forms part of ING Group (being for this purpose ING Group N.V. and its subsidiary and affiliated companies)*. The information in the publication is not an investment recommendation and it is not investment, legal or tax advice or an offer or solicitation to purchase or sell any financial instrument. Reasonable care has been taken to ensure that this publication is not untrue or misleading when published, but ING does not represent that it is accurate or complete. ING does not accept any liability for any direct, indirect or consequential loss arising from any use of this publication. Unless otherwise stated, any views, forecasts, or estimates are solely those of the author(s), as of the date of the publication and are subject to change without notice.

The distribution of this publication may be restricted by law or regulation in different jurisdictions and persons into whose possession this publication comes should inform themselves about, and observe, such restrictions.

Copyright and database rights protection exists in this report and it may not be reproduced, distributed or published by any person for any purpose without the prior express consent of ING. All rights are reserved. ING Bank N.V. is authorised by the Dutch Central Bank and supervised by the European Central Bank (ECB), the Dutch Central Bank (DNB) and the Dutch Authority for the Financial Markets (AFM). ING Bank N.V. is incorporated in the Netherlands (Trade Register no. 33031431 Amsterdam). In the United Kingdom this information is approved and/or communicated by ING Bank N.V., London Branch. ING Bank N.V., London Branch is authorised by the Prudential Regulation Authority and is subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. ING Bank N.V., London branch is registered in England (Registration number BR000341) at 8-10 Moorgate, London EC2 6DA. For US Investors: Any person wishing to discuss this report or effect transactions in any security discussed herein should contact ING Financial Markets LLC, which is a member of the NYSE, FINRA and SIPC and part of ING, and which has accepted responsibility for the distribution of this report in the United States under applicable requirements.

Additional information is available on request. For more information about ING Group, please visit <http://www.ing.com>.